Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial
Two diabetes medications improve how blood vessels function, potentially reducing heart disease risk in people with type 2 diabetes.
This PubMed-indexed randomized controlled trial examines Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. The available abstract reports The endothelium maintains vascular health by regulating blood flow and protecting against inflammatory damage In type 2 diabetes (T2DM), however, hyperglycemia, hypertension, and hyperlipidemia place a significant burden on the endothelium, potentially leading to atherosclerosis and cardiovascular disease (CVD).
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants
- Category
- Other
- Maturity
- Validated
- Journal
- Journal of diabetes and its complications
Why it surfaced
Conservative rapid triage: randomized controlled trial, human evidence, and direct relevance to Cardiovascular-metabolic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.